What's in Teva Pharmaceuticals USA's pipeline?

Teva Pharmaceuticals USA has 23 drugs in our index: 14 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 7 in Phase 1.

Which companies overlap with Teva Pharmaceuticals USA's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Bayer, Organon and Co, Galderma R&D, Arbor Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/teva-pharmaceuticals-usa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Teva Pharmaceuticals USA — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teva Pharmaceuticals USA pipeline: 14 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

14 marketed 0 filed 2 Phase 3 0 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cefzil	cefprozil	marketed	Cephalosporin Antibacterial [EPC]		Infectious Disease	1991-01-01
Paxil®	Paxil®	marketed
YAZ®	YAZ®	marketed	Oral contraceptive (combined estrogen-progestin)	Progesterone receptor, estrogen receptor, mineralocorticoid receptor	Contraception / Gynecology
FEMCON® Fe	FEMCON® Fe	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen and progesterone receptors; LH/FSH suppression	Contraception / Women's Health
Azelastine hydrochloride and Fluticasone propionate	Azelastine hydrochloride and Fluticasone propionate	marketed
Zofran®	Zofran®	marketed
Imitrex®	Imitrex®	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B and 5-HT1D receptors	Neurology
Lamictal®	Lamictal®	marketed
Activella®	Activella®	marketed
Augmentin®	Augmentin®	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); beta-lactamase enzymes	Infectious Disease
Trileptal®	Trileptal®	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels	Neurology
VTAMA®	VTAMA®	marketed	Retinoid X receptor (RXR) agonist	Retinoid X receptor (RXR)	Dermatology

Therapeutic area mix

Dermatology · 3
Infectious Disease · 2
Neurology · 2
Contraception / Gynecology · 1
Contraception / Women's Health · 1
Cardiovascular · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
Bayer · 3 shared drug classes
Organon and Co · 3 shared drug classes
Galderma R&D · 2 shared drug classes
Arbor Pharmaceuticals, Inc. · 1 shared drug class
Asian Institute of Gastroenterology, India · 1 shared drug class
Affiliated Hospital of Nantong University · 1 shared drug class
Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Teva Pharmaceuticals USA:

Cite this brief

Drug Landscape (2026). Teva Pharmaceuticals USA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/teva-pharmaceuticals-usa. Accessed 2026-06-10.